The influence of first generation (Everolimus) and second generation (KU-0063794) mTOR inhibitors on the mTOR pathway in N-HCC25 cells was explored, as mTOR is a major regulator of cell growth and a target for pharmacological treatment of HCC in clinical studies. Here, MTOR is linked to hepatocellular carcinoma.